NASDAQ : REPL
Replimune Group, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 17.61 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.67B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.85B |
| Enterprise Value | 1.67B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 28, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 94.80M |
| Shares Outstanding | 94.80M |
| Shares Change (YoY) | +8.94% |
| Shares Change (QoQ) | +8.58% |
| Owned by Insiders (%) | 1.58% |
| Owned by Institutions (%) | 77.25% |
| Float | 68.23M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 21.17 |
| PB Ratio | 9.02 |
| P/TBV Ratio | 9.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 7.11 |
| Quick Ratio | 6.76 |
| Debt / Equity | 0.62 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -24.47 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -115.80% |
| Return on Assets (ROA) | -43.95% |
| Return on Invested Capital (ROIC) | -49.95% |
| Return on Capital Employed (ROCE) | -81.73% |
| Weighted Average Cost of Capital (WACC) | 9.24% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$582,869 |
| Employee Count | 465 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -551,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.94 |
| 52-Week Price Change | +100.31% |
| 50-Day Moving Average | 13.67 |
| 200-Day Moving Average | 9.36 |
| Relative Strength Index (RSI) | 79.64 |
| Average Volume (20 Days) | 2,758,479 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 23.17M |
| Short Previous Month | 23.13M |
| Short % of Shares Out | 24.44% |
| Short % of Float | 33.95% |
| Short Ratio (days to cover) | 11.50 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -268.39M |
| Pretax Income | -271.59M |
| Net Income | -271.03M |
| EBITDA | -262.64M |
| EBIT | -268.39M |
| Earnings Per Share (EPS) | -$2.78 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 307.83M |
| Total Debt | 127.19M |
| Net Cash | 180.64M |
| Net Cash Per Share | $1.91 |
| Equity (Book Value) | 204.78M |
| Book Value Per Share | 2.16 |
| Working Capital | 278.48M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -245.55M |
| Capital Expenditures | -223,000 |
| Depreciation & Amortization | 5.76M |
| Net Borrowing | 49.19M |
| Free Cash Flow | -245.77M |
| FCF Per Share | -$2.59 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -8.94% |
| Shareholder Yield | -8.94% |
| Earnings Yield | -14.27% |
| FCF Yield | -13.30% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $23.33 |
| Price Target Difference | 19.70% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |